Keywords
Lung Neoplasms ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

58 Search results.

Eligibility Neuroendocrine Carcinoma of the Lung and Thymus NCT01563354

- 11/10/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial; ODM derived from: https://clinicaltrials.gov/show/NCT01563354 according to the information on clinicaltrials.gov "other protocol-defined inclusion/exclusion-criteria may apply"

Eligibility Lung Neoplasms NCT01266512

- 7/11/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01266512

Eligibility Lung Neoplasms NCT01717482

- 7/11/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01717482

Eligibility Lung Cancer NCT02134015

- 7/10/20 - 1 form, 2 itemgroups, 32 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung); ODM derived from: https://clinicaltrials.gov/show/NCT02134015

Eligibility Lung Neoplasms NCT01109524

- 7/10/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01109524

Eligibility Lung Carcinoma NCT02285660

- 7/10/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition; ODM derived from: https://clinicaltrials.gov/show/NCT02285660

Eligibility Lung Cancer NCT02115464

- 7/10/20 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02115464

Eligibility Lung Cancer NCT01503385

- 7/8/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01503385

Eligibility Lung Cancer NCT01594398

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01594398

Eligibility Lung Cancer NCT00832715

- 7/8/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00832715

Eligibility Lung Cancer NCT01514877

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01514877

Eligibility Lung Cancer NCT01562028

- 7/8/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01562028